The Supernova All-Stars semifinal featured 100 startups from around the world, including three projects from Kazakhstan: ARLAN BIOTECH, Beksar, and Qala AI Ltd. Following the selection process, 10 teams advanced to the final. The startups were evaluated by an international jury consisting of venture investors, industry experts, and representatives of corporate funds.
The key evaluation criteria included:
-
technological novelty,
-
market potential,
-
sustainability of the business model,
-
product readiness stage,
-
team qualifications.
ARLAN BIOTECH presented a solution that accelerates drug development using its proprietary generative AI–based platform. The platform makes it possible to generate accurate antibody sequences for specific protein targets within minutes, reducing research timelines by six months and cutting pharmaceutical companies’ costs by millions of dollars. The technology is based on the startup’s own AI model and synthetic biomedical data, enabling the parallel development of dozens of solutions. The startup was founded by a PhD in biomedical engineering, a programmer with more than 10 years of experience in biotech entrepreneurship, and an AI specialist with six years of experience developing medical AI solutions.
“It is important to note that all three prize-winning startups are deeptech projects founded by PhD-level founders. This confirms that the technological landscape is rapidly shifting toward science-driven solutions. I believe in the potential of deeptech entrepreneurs from our region, and especially from Kazakhstan. More and more often, I hear that Central Asia is one of the most promising regions for the development of the global startup ecosystem. I would like to thank Astana Hub and the Ministry of Digital Development of Kazakhstan for their support, which made it possible for us to represent Kazakhstan on this international platform,” said Bolat Sultankulov, co-founder of ARLAN BIOTECH.
Read more on Er10.kz.
The Supernova All-Stars semifinal featured 100 startups from around the world, including three projects from Kazakhstan: ARLAN BIOTECH, Beksar, and Qala AI Ltd. Following the selection process, 10 teams advanced to the final. The startups were evaluated by an international jury consisting of venture investors, industry experts, and representatives of corporate funds.
The key evaluation criteria included:
-
technological novelty,
-
market potential,
-
sustainability of the business model,
-
product readiness stage,
-
team qualifications.
ARLAN BIOTECH presented a solution that accelerates drug development using its proprietary generative AI–based platform. The platform makes it possible to generate accurate antibody sequences for specific protein targets within minutes, reducing research timelines by six months and cutting pharmaceutical companies’ costs by millions of dollars. The technology is based on the startup’s own AI model and synthetic biomedical data, enabling the parallel development of dozens of solutions. The startup was founded by a PhD in biomedical engineering, a programmer with more than 10 years of experience in biotech entrepreneurship, and an AI specialist with six years of experience developing medical AI solutions.
“It is important to note that all three prize-winning startups are deeptech projects founded by PhD-level founders. This confirms that the technological landscape is rapidly shifting toward science-driven solutions. I believe in the potential of deeptech entrepreneurs from our region, and especially from Kazakhstan. More and more often, I hear that Central Asia is one of the most promising regions for the development of the global startup ecosystem. I would like to thank Astana Hub and the Ministry of Digital Development of Kazakhstan for their support, which made it possible for us to represent Kazakhstan on this international platform,” said Bolat Sultankulov, co-founder of ARLAN BIOTECH.
Read more on Er10.kz.
Share
